



Topic Suggestions....Contact:
Pharmaceutical Services Division
Health and Community Services
P.O. Box 8700
St. John's, NL A1B 4J6
Tel: 729-6507 Fax: 729 -2851

Department of Health
and Community Services

Spring 2010

Behind the Scenes

Newfoundland and Labrador Prescription Drug Program (NLPDP)

SPECIAL AUTHORIZATION REQUEST FORMS



Special Authorization request forms are available on the NLPDP website <http://www.health.gov.nl.ca/health/nlpdp/> in the Special Authorization Drugs section. There is a standard form as well as specialized forms for Cholinesterase Inhibitors, Clopidogrel, Sevelamer, Methadone, Crohn's Disease medications (anti-TNF agents), Psoriasis and Rheumatoid Arthritis medications. These forms are a good guide as to what information is needed for assessment for coverage and are being regularly updated to reflect NLPDP changes. Older forms should not be used.

DOCTOR WHO?



Special authorization requests should include the requesting prescriber's name (printed), license number and contact information. This is helpful for communicating the results of the special authorization assessment including coverage details and any reassessment needed for coverage renewal as well as requesting additional information that may be needed to complete an assessment for coverage.

PATIENT MCP NUMBER NEEDED FOR SPECIAL AUTHORIZATION REQUESTS



Please be advised that the MCP number is mandatory when requesting Special Authorization or when making an enquiry on behalf of a patient. For requests that do not have MCP number identification the sender will be contacted and the request will be delayed until MCP number is provided. Health care providers making an enquiry on behalf of a patient will be required to give their license number as a means of identification to ensure privacy is maintained.

THE NEWFOUNDLAND AND LABRADOR INTERCHANGEABLE FORMULARY

New Categories Effective September 13, 2009:

Lansoprazole Delayed Release 15mg

Lansoprazole Delayed Release 30mg

New Categories Effective November 6, 2009:

Amlodipine 5mg

Amlodipine 10mg

Ramipril 15mg

Rivastigmine 1.5mg

Rivastigmine 3mg

Rivastigmine 4.5mg

Rivastigmine 6mg

Ropinirole 0.25mg

Ropinirole 1mg

Ropinirole 2mg

Ropinirole 5mg

Levofloxacin 750mg*

Carbidopa/Levodopa 25mg/100mg CR

New Categories Effective January 1, 2010:

Olanzapine ODT 5mg

Olanzapine ODT 10mg

Olanzapine ODT 15mg

*Not covered by NLPDP

Olanzapine ODT 20mg*

Olanzapine 20mg*

CHANGES TO THE NLPDP BENEFIT LISTING

New open benefits for Foundation, 65Plus, Access and Assurance Plans

Lucentis DIN 02296810 (when prescribed by a registered Ophthalmologist)

Zithromax 250mg DIN 02212021 and generic equivalents

Zithromax 100mg/5ml suspension DIN 02223716 and generic equivalents

Zithromycin 200mg/5ml DIN 02223724 and generic equivalents

Norvasc 5mg DIN 00878928 and generic equivalents

Norvasc 10mg DIN 00878936 and generic equivalents

Flomax SR DIN 02238123 and generic equivalents

Flomax CR DIN 02270102

Novo-Quetiapine 150mg DIN 02284251

Cytomel 5ug DIN 01919458

Cytomel 25ug DIN 01919466

Azopt 1% ophthalmic drops DIN 02238873

Special Authorization

Coverage criteria can be viewed at <http://www.health.gov.nl.ca/health/nlpdp/>

The following medications are now being considered under Special Authorization for Foundation, Access, 65Plus and Assurance Plans:

| | |
|--|-----------------------|
| Vesicare (5mg DIN 02277263, 10mg DIN 02277271) | Overactive Bladder |
| Prezista (300mg DIN 02284057, 400mg DIN 02324016, 600mg DIN 02324024) | HIV - treatment naive |
| Wellbutrin XL (150mg DIN 02275090, 300mg DIN 02275104) | Depression |

The **Common Drug Review (CDR)** reviews new drugs and provides an evidence-based formulary listing recommendation, made by the [Canadian Expert Drug Advisory Committee \(CEDAC\)](#), on behalf of participating publicly-funded drug plans. Reviews for the following products were completed by the Common Drug Review and coverage was not recommended. As such, these products will not be considered for coverage under the NLPDP. CEDAC recommendations can be viewed at www.cadth.ca

Inspira 25mg DIN 02323052

Vyvanse 30mg DIN 02322951

Pristiq 50mg DIN 02321092

Inspira 50mg DIN 02323060

Vyvanse 50mg DIN 02322978

Pristiq 100mg DIN 02321106